Lauren Harshman MD, Co-director of Kidney Cancer Program Dana-Farber Cancer Institute/Harvard Medical School discusses Biologic Rational For Neoadjuvant OVER Adjuvant…
Browsing: Acute Lymphoblastic Leukemia
Axel Bex, The Netherlands Cancer Institute Amsterdam debates the side of No Adjuvant Therapy Kidney Cancer at the 13th European…
Michael Staehler, Ludwig-Maximilians-University of Munich | LMU discusses Yes for Adjuvant Therapy with Full Dose VEGFR TKI at the 13th…
Maxine Tran, Senior lecturer and Honorary Consultant Urologist Specialist center for kidney cancer, Royal Free Hospital UCL Division of Surgery…
Tom Mitchell BMBCh, DPhil, FRCS, Academic Clinical Lecturer & Honorary Urology Registrar, Cambridge University Hospitals discusses Timing of Key Genetic…
Grant D Stewart, University Lecturer, University of Cambridge, Consultant Urological Surgeon, Addenbrookes Hospital asks the question “Screening for kidney cancer:…
The British Society for Haematology (BSH) aims to improve patient care and outcomes in the hematology field. In this interview,…
The British Society for Haematology (BSH) brings hematology professionals from all areas together at their Annual Scientifc Meeting. Speaking from…
IMPACT, the UKs first large-scale clinical trials platform for patients receiving a stem cell transplant, is launching in 2018. Here,…
Recent KEYNOTE study data has led to confusion over the significance of PD-L1 as a predictive biomarker of immunotherapy response.…
The results of KEYNOTE-024 (NCT02142738) indicated that high PD-L1 expression predicted a benefit from pembrolizumab vs. chemotherapy. However, new data…
Dr. Jack West reviews the trial design, efficacy endpoints, and toxicity results of the KEYNOTE-189 trial of pembrolizumab or placebo…
A Practice Change for ALK+ Lung Cancer Patients, Alecensa for First Line Treatment
Sequencing Treatments for ALK+ Lung Cancer in a Crowded Field Is there a place for Lorlatinib?
Are MET Mutations Now a Mutation We Should Look for in Lung Cancer?
Dacomitinib Beats Iressa as First Line Treatment for EGFR Mutation-Positive NSCLC: New Option or Too Little Too Late?
Keytruda is Now Approved in Combination with Chemo for Advanced Non-Squamous NSCLC: What Do We Do Now?
What is PFS2 in Advanced NSCLC, and Should we Care? Unique Analysis of the KEYNOTE-024 trial     …
What is the role for Immunotherapy in Relapsed Small Cell Lung Cancer after ASCO 2017?
Emerging Options for Malignant Pleural Mesothelioma
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes strategies for treatment of the elderly and frail patient with locally…
Radiation oncologist Dr. Chris Loiselle reviews the possibility of re-treating with radiation for lung cancer, typically using stereotactic technique, in…
Why radiate a perfectly good brain? Dr. Vivek Mehta, radiation oncologist, discusses the possible role for prophylactic cranial irradiation (PCI)…
Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor…
MSKCC medical oncologist Dr. Greg Riely reviews the optimal first line treatment of patients with an EGFR mutation-positive advanced lung…
Drs. Leora Horn, Ben Solomon, & Jack West consider the merits of administering immune checkpoint inhibitors concurrently with standard first…
Drs. Leora Horn, Ben Solomon, & Jack West debate whether results from a European trial of chest radiation after chemotherapy…
Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib…
Dr. Nasser Hanna, Indiana University Health, describes the factors which determine whether stage III NSCLC is resectable.
Join us for the 2017 Targeted Therapies in Lung Cancer Patient Forum, Saturday, September 16, 2017, at the Taussig Cancer…
Afternoon Session – Targeted Therapies in Lung Cancer Patient Forum Breakout Webcast Recording – MET/RET/BRAF, with Dr. Karen Reckamp, Dr.…
Dr. Jame Abraham, Director of the Breast Oncology program at Taussig Cancer Institute and Co-Director of the Cleveland Clinic Lerner…
In this weeks video, Dr. Brian G.M. Durie explains which criteria and tests determine if a patients myeloma is smoldering…
Radical thoracic radiotherapy is a mainstay in the treatment of non-small cell lung cancer (NSCLC); however, the effect of cardiac…
In this weeks video, Dr. Brian G.M. Durie explains that maintenance therapy can prolong remissions and delay relapse. The BOTTOM…
In this weeks video, Dr. Brian G.M. Durie explains that if you relapse on Darzalex, it is important to carefully…
In this weeks video, Dr. Brian G.M. Durie explains why genetic sequencing tests are not yet precise enough to use…
The anti-PD-1 antibody therapy pembrolizumab is an exciting new agent for the treatment of non-small cell lung cancer (NSCLC). Here,…
The IMpower150 trial (NCT02366143) was the first to explore chemotherapy, immunotherapy with atezolizumab and anti-angiogenic therapy with bevacizumab for non-small…
Immunotherapeutic agents are increasingly becoming incorporated into clinical practice; however, there is still much to learn, including their optimal combinations,…
The Phase III KEYNOTE-024 trial (NCT02142738) compared pembrolizumab monotherapy with standard platinum-based chemotherapy for previously untreated metastatic non-small cell lung…
The European Lung Cancer Congress (ELCC) 2018, in Geneva, Switzerland, presented an array of exciting lung cancer trial updates. Speaking…
Anti-angiogenic therapy has proven to be useful tool for the treatment of non-small cell lung cancer (NSCLC) in the frontline…
The treatment of brain metastases in non-small cell lung cancer (NSCLC) is a challenge, as the majority of the drugs…
Due to constraints within the NHS treatment pathway, patients with newly diagnosed multiple myeloma (MM) who are characterized as having…
Despite the controversy surrounding the design of the Tackling EArly Morbidity and Mortality in Myeloma (TEAMM) trial (ISRCTN51731976), a Phase…
In 2016, 250 patients with relapsed and/or refractory multiple myeloma (MM) were enrolled onto the Myeloma UK (MUK) Seven trial…
An exciting update on the CASTOR trial was presented at the American Society of Hematology (ASH) 2017 Annual Meeting and…
Is the addition of cyclophosphamide to pomalidomide (Pom) and dexamethasone (Dex) treatment more effective at inducing a deeper and more…